Trial Profile
To describe factors associated with vedolizumab failure or need for dose escalation in patients with UC and CD receiving vedolizumab therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jan 2017
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Therapeutic Use
- 09 Jan 2017 New trial record